Anti-Human PD-L1 (Atezolizumab Biosimilar)
Catalog #500006
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500006 | 1 mg | $200.00 | ||
| 500006 | 5 mg | $600.00 | ||
| 500006 | 20 mg | $1,400.00 |
Product Details
Atezolizumab biosimilar is a programmed death-ligand 1 (PD-L1) inhibitor, designed to restore anti-tumor immune responses by preventing PD-L1 from interacting with PD-1 and B7.1 receptors. This immune checkpoint inhibitor (ICI) enhances T-cell activation and promotes the immune system's ability to detect and attack cancer cells.
Specifications
| Clone | Atezolizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human PD-L1 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |